Supernus Pharmaceuticals Hits New 52-Week High of $53.28

Supernus Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 53.28 on October 24, 2025. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly impressive given its market capitalization of USD 2,569 million, categorizing it as a small-cap stock.
Over the past year, Supernus Pharmaceuticals has demonstrated remarkable growth, with a performance increase of 101.72%, significantly outpacing the S&P 500's 16.9% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 29.00, reflecting its valuation in the market. Additionally, Supernus maintains a debt-to-equity ratio of -0.48, indicating a strong financial position with minimal reliance on debt.

Despite not offering a dividend, the company has achieved a return on equity of 6.51%, and its price-to-book ratio is 2.42. The stock's previous 52-week low was recorded at USD 29.16, highlighting the substantial upward movement in its price. This performance positions Supernus Pharmaceuticals favorably within its industry.